Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection : a target trial emulation
© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc..
To date, there is a lack of randomized trial data examining the use of the antiviral nirmatrelvir/ritonavir in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected pregnant persons. This target trial emulation study aimed to address this gap by evaluating the use of nirmatrelvir/ritonavir in nonhospitalized pregnant women with symptomatic SARS-CoV-2 Omicron variant infection. Among patients diagnosed between 16 March 2022 and 5 February 2023, exposure was defined as outpatient nirmatrelvir/ritonavir treatment within 5 days of symptom onset or coronavirus disease 2019 (COVID-19) diagnosis. Primary outcomes were maternal morbidity and mortality index (MMMI), all-cause maternal death and COVID-19-related hospitalization, while secondary outcomes were individual components of MMMI, preterm birth, stillbirth, neonatal death and cesarean section. One-to-ten propensity-score matching was conducted between nirmatrelvir/ritonavir users and nonusers, followed by cloning, censoring and weighting. Overall, 211 pregnant women on nirmatrelvir/ritonavir and 1,998 nonusers were included. Nirmatrelvir/ritonavir treatment was associated with reduced 28-day MMMI risk (absolute risk reduction (ARR) = 1.47%, 95% confidence interval (CI) = 0.21-2.34%) but not 28-days COVID-19-related hospitalization (ARR = -0.09%, 95% CI = -1.08% to 0.71%). Nirmatrelvir/ritonavir treatment was also associated with reduced risks of cesarean section (ARR = 1.58%, 95% CI = 0.85-2.39%) and preterm birth (ARR = 2.70%, 95% CI = 0.98-5.31%). No events of maternal or neonatal death or stillbirth were recorded. The findings suggest that nirmatrelvir/ritonavir is an effective treatment in symptomatic pregnant women with SARS-CoV-2 Omicron variant infection.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
---|---|
Enthalten in: |
Nature medicine - 30(2024), 1 vom: 01. Jan., Seite 112-116 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Wong, Carlos K H [VerfasserIn] |
---|
Links: |
---|
Themen: |
7R9A5P7H32 |
---|
Anmerkungen: |
Date Completed 01.02.2024 Date Revised 01.02.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41591-023-02674-0 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM364057114 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM364057114 | ||
003 | DE-627 | ||
005 | 20240202232033.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41591-023-02674-0 |2 doi | |
028 | 5 | 2 | |a pubmed24n1278.xml |
035 | |a (DE-627)NLM364057114 | ||
035 | |a (NLM)37913816 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Wong, Carlos K H |e verfasserin |4 aut | |
245 | 1 | 0 | |a Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection |b a target trial emulation |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 01.02.2024 | ||
500 | |a Date Revised 01.02.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. The Author(s), under exclusive licence to Springer Nature America, Inc. | ||
520 | |a To date, there is a lack of randomized trial data examining the use of the antiviral nirmatrelvir/ritonavir in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected pregnant persons. This target trial emulation study aimed to address this gap by evaluating the use of nirmatrelvir/ritonavir in nonhospitalized pregnant women with symptomatic SARS-CoV-2 Omicron variant infection. Among patients diagnosed between 16 March 2022 and 5 February 2023, exposure was defined as outpatient nirmatrelvir/ritonavir treatment within 5 days of symptom onset or coronavirus disease 2019 (COVID-19) diagnosis. Primary outcomes were maternal morbidity and mortality index (MMMI), all-cause maternal death and COVID-19-related hospitalization, while secondary outcomes were individual components of MMMI, preterm birth, stillbirth, neonatal death and cesarean section. One-to-ten propensity-score matching was conducted between nirmatrelvir/ritonavir users and nonusers, followed by cloning, censoring and weighting. Overall, 211 pregnant women on nirmatrelvir/ritonavir and 1,998 nonusers were included. Nirmatrelvir/ritonavir treatment was associated with reduced 28-day MMMI risk (absolute risk reduction (ARR) = 1.47%, 95% confidence interval (CI) = 0.21-2.34%) but not 28-days COVID-19-related hospitalization (ARR = -0.09%, 95% CI = -1.08% to 0.71%). Nirmatrelvir/ritonavir treatment was also associated with reduced risks of cesarean section (ARR = 1.58%, 95% CI = 0.85-2.39%) and preterm birth (ARR = 2.70%, 95% CI = 0.98-5.31%). No events of maternal or neonatal death or stillbirth were recorded. The findings suggest that nirmatrelvir/ritonavir is an effective treatment in symptomatic pregnant women with SARS-CoV-2 Omicron variant infection | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Randomized Controlled Trial | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Lactams |2 NLM | |
650 | 7 | |a Leucine |2 NLM | |
650 | 7 | |a GMW67QNF9C |2 NLM | |
650 | 7 | |a nirmatrelvir |2 NLM | |
650 | 7 | |a 7R9A5P7H32 |2 NLM | |
650 | 7 | |a Nitriles |2 NLM | |
650 | 7 | |a Proline |2 NLM | |
650 | 7 | |a 9DLQ4CIU6V |2 NLM | |
650 | 7 | |a Ritonavir |2 NLM | |
650 | 7 | |a O3J8G9O825 |2 NLM | |
700 | 1 | |a Lau, Kristy T K |e verfasserin |4 aut | |
700 | 1 | |a Chung, Matthew S H |e verfasserin |4 aut | |
700 | 1 | |a Au, Ivan C H |e verfasserin |4 aut | |
700 | 1 | |a Cheung, Ka Wang |e verfasserin |4 aut | |
700 | 1 | |a Lau, Eric H Y |e verfasserin |4 aut | |
700 | 1 | |a Daoud, Yasmin |e verfasserin |4 aut | |
700 | 1 | |a Cowling, Benjamin J |e verfasserin |4 aut | |
700 | 1 | |a Leung, Gabriel M |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Nature medicine |d 1995 |g 30(2024), 1 vom: 01. Jan., Seite 112-116 |w (DE-627)NLM074659804 |x 1546-170X |7 nnns |
773 | 1 | 8 | |g volume:30 |g year:2024 |g number:1 |g day:01 |g month:01 |g pages:112-116 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41591-023-02674-0 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 30 |j 2024 |e 1 |b 01 |c 01 |h 112-116 |